Lead Product(s) : Cefepime,Zidebactam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : ICICI Prudential
Deal Size : $57.5 million
Deal Type : Private Placement
Wockhardt Raises Rs 480 Crore to Pare Debt, Fund Drug Trial
Details : WCK 5222, a combination of cefepime and zidebactam, is in a Phase 3 trial for complicated urinary tract infections globally.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
March 28, 2024
Lead Product(s) : Cefepime,Zidebactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : ICICI Prudential
Deal Size : $57.5 million
Deal Type : Private Placement
Lead Product(s) : Zidebactam
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Quintiles Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 04, 2016
Lead Product(s) : Zidebactam
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Quintiles Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zidebactam
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Quintiles Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 25, 2015
Lead Product(s) : Zidebactam
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Quintiles Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
